The pso Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the pso Hub cannot guarantee the accuracy of translated content. The pso and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The PsOPsA Hub is supported by educational grants. All educational content is developed independently by SES in collaboration with our expert steering committee, with no input or influence from financial supporters. We would like to express our gratitude to the following companies for their support: • UCB: For website development, launch, and ongoing maintenance. • UCB: For educational content and news updates.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View pso content recommended for you
Guselkumab vs adalimumab for moderate-to-severe plaque psoriasis: A biomarker analysis from the VOYAGE 1 trial
|
In the phase III VOYAGE 1 trial (NCT02207231), guselkumab, a fully human monoclonal antibody that inhibits interleukin (IL)-23, demonstrated superior efficacy vs placebo and adalimumab, a tumor necrosis factor-α (TNF-α) inhibitor, in patients with moderate-to-severe plaque psoriasis.1 Results from a biomarker analysis of a subset of patients in the VOYAGE 1 trial were published in JID Innovations by Blauvelt, et al.1 |
| Key learnings: |
|
While both guselkumab and adalimumab reduced serum levels of key cytokines IL-17A, IL-17F, and IL-22 from baseline at Weeks 4, 24, and 48 (p < 0.001 and p < 0.01, respectively), reductions were greater with guselkumab for IL-17A at Weeks 4 and 48 (p < 0.05), IL-17F at Weeks 4, 24, and 48 (p < 0.05), and IL-22 at Weeks 4 and 48 (p < 0.05), highlighting its superior efficacy in modulating the IL-23/IL-17 pathway in psoriasis. |
|
Treatment with guselkumab led to a more significant impact on the molecular drivers of psoriasis, as demonstrated by a greater normalization of psoriasis-associated gene expression in lesional skin samples at all assessed time points compared with adalimumab. |
|
The molecular pharmacodynamic findings from the study results are consistent with the clinical responses observed in the VOYAGE 1 trial. |
|
The results from this study demonstrate that targeted blockade of the IL-23 pathway with guselkumab may offer improved long-term control of moderate-to-severe plaque psoriasis compared with the broader TNF-α blockade by adalimumab. |
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
